459133-43-8

Basic information

• Product Name: methyl (R)-2-amino-3-(4-bromophenyl)propanoate hydrochloride
• Synonyms: methyl (R)-2-amino-3-(4-bromophenyl)propanoate hydrochloride
• CAS NO: 459133-43-8
• Molecular Weight: 294.576
• Mol File: 459133-43-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: methyl (R)-2-amino-3-(4-bromophenyl)propanoate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: methyl (R)-2-amino-3-(4-bromophenyl)propanoate hydrochloride(459133-43-8)
• EPA Substance Registry System: methyl (R)-2-amino-3-(4-bromophenyl)propanoate hydrochloride(459133-43-8)

Safety Data

• Hazardous Substances Data: 459133-43-8(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 62561-74-4 (2R)-2-amino-3-(4-bromophenyl)propanoic acid 

Downstream Products

• 149818-98-4 methyl (R)-α-<<(1,1-dimethylethoxy)carbonyl>amino><1,1'-biphenyl>-4-propanoate 
• 1426129-50-1 N-[(1R)-2-[1,1'-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester 
• 1213855-60-7 methyl (R)-3-(4-bromophenyl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 1431556-44-3 C₁₃H₁₆BrNO₄ 

Relevant articles and documents

Rhodium-Catalyzed Enantioselective Synthesis of Oxazinones via an Asymmetric Ring Opening-Lactonization Cascade of Oxabicyclic Alkenes

The rhodium-catalyzed asymmetric ring opening reaction of oxabicyclic alkenes is shown to be an efficient method for synthesizing chiral heterocycles. We demonstrate that the pairwise combination of chiral catalyst with chiral amino-acid-derived pronucleophiles results in a stereodivergent synthesis of diastereomeric hydroxyesters. A favorable conformational preference induces the subsequent lactonization of one diastereomer leading to the highly enantioselective synthesis of oxazinones.

HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE

Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4′-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.